Loading provider…
Loading provider…
Neurology Physician in New York, NY
NPI: 1295726404Primary Practice Location
MOUNT SINAI BETH ISRAEL
281 1st Ave, New York, NY
Primary Employer
Neurology Department of Mount Sinai
mountsinai.org
HQ Phone
Get MD Susan's Phone Numberphone_androidMobile
Get MD Susan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
FL State Medical License
2020
NY State Medical License
1978 - 2025

American Board of Psychiatry and Neurology
Neurology
New York Presbyterian Hospital (Columbia Campus)
Residency • Neurology
1978 - 1982
New York Presbyterian Hospital (Cornell Campus)
Internship • Internal Medicine
1977 - 1978
Vagelos College of Physicians and Surgeons
vagelos.columbia.edu
Medical School
Until 1977
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 127 | 244 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 70 | 92 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 19 | 22 |
Association of a missense change in the D2 dopamine receptor with myoclonus dystonia.
Authors: Mitchell Brin
Journal: Proc Natl Acad Sci U S A
Genetic linkage analysis in primary torsion dystonia
Authors: Bressman, S B, Fahn, S, Falk, C, Allen, F H, Suciu-Foca, N
Journal: Neurology
Diagnosis and referral delay in women with Parkinson's disease.
Authors: Rachel Saunders Pullman
Journal: Gend Med
Lead Sponsor: Northwestern University
Collaborators: Michael J. Fox Foundation for Parkinson's Research, University of Rochester, University of Iowa
Intervention / Treatment: DRUG: Placebo, DRUG: Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), DRUG: Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)
Lead Sponsor: Michael J. Fox Foundation for Parkinson's Research
Collaborators: Institute for Neurodegenerative Disorders
Lead Sponsor: Parkinson's Foundation
Collaborators: Indiana University, The Parkinson Study Group, Fulgent Laboratories, Navitas Clinical Research, Inc
Intervention / Treatment: DEVICE: Lab Assay for seven genetic variants for Parkinson's Disease